Begin typing your search above and press return to search.
Volume: 6 Issue: 4 November 2008 - Supplement - 1

FULL TEXT

OPTIMIZING THE HAEMATOPOIETIC RESPONSE TO EPOTIN® ON MAINTENANCE HAEMODIALYSIS END STAGE KIDNEY DISEASE PATIENTS

Recombinant human erythropoietin (rHuEpo) has revolutionized the management of renal anemia and has significantly improved patients’ quality of life. Great attention has been paid lately how to optimally use this potent anti-anemic agent. Aiming to overview anemic patients management with Epotin (Julphar`s rHuEpo) according to the new guidelines. Anemic (Hb< 11 g/dL) ESKD patients (n=35) with age > 18 years, iron replete (TSAT ≥ 20% and serum ferritin ≥ 100 mcg/L), and with no serious inflammation (CRP less than 30 mg/l) on thrice weekly heamodialysis were included in the study. Mean age and dialysis durations in years were 50.8 + 17 and 3.8 + 2.8 respectively. 88.6% (n=31) patients were de novo patients on corrective phase with no previous exposure to erythropoietin. All safety-efficacy influential parameters were monitored and showed insignificant changes throughout the study 4-month period, including iron profile that was maintained according to K-DOQI guidelines. Efficacy parameters revealed a significant increase (P value <0.0001) of Hb levels from baseline of 8.5 + 1.0 to 11.1 + 1.1. Targeting an absolute increase of 2.5 g/dl in Hb throughout 3 months of the study period resulted in 90.3% success rate. Safety wise, no dropouts were recorded due to intolerance, while all the recorded adverse events were classified as unrelated to the test product. In conclusion, Epotin® is clinically effective to correct and maintain Hb levels, in ESKD anemic patients on maintenance haemodialysis, within the current recommended range and with a satisfactory safety profile in line with what is reported internationally.



Volume : 6
Issue : 4
Pages : 208


PDF VIEW [1191] KB.

Dubai Research Center, UAE